Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-043 manufacturers

Filters

1 products found

pp-043

Solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Advanced or metastatic solid tumours (e.g., non-small cell lung cancer, head & neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, malignant melanoma). Clinical stage / status: Phase 1 ( trial in the USA). Mechanism / differentiating features: Human monoclonal antibody targeting LILRB1 (Leukocyte Immunoglobulin-Like Receptor B1) — blocks the binding of tumour-expressed HLA-G to LILRB1 on immune cells, thereby activating multiple immune cell types (T cells, NK cells, macrophages) simultaneously. Route / form: Intravenous infusion of the monoclonal antibody. Differentiation / unmet need: unique mechanism engaging multiple immune cell types rather than just T-cells; addresses solid tumor patients who have progressed on standard treatments.
Manufacturer #16907

This South Korea–based life-sciences organization develops a portfolio of small-molecule and biologic therapeutics, with a strategic focus on oncology, immunology, and metabolic diseases. Its pharmaceutical R&D is supported by global clinical programs and collaborations aimed at advancing first-in-class and best-in-class candidates. The group also maintains established therapeutic franchises and leverages international partnerships to expand its presence in the global healthcare market.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.